A CLASS ACT : THE MINOR GROOVE BINDER
Both New Class and New Mechanism of Action
MGB Biopharma Limited commenced operations in 2010 to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGBs)
The company's experienced team with significant track record in the big pharma and biotech sectors has dedicated its initial focus to the development of small molecules with specific antibacterial effects against resistant bacteria.
There are many drugs used to treat bacterial infections and they mostly belong to classes which have been in use for several decades. Due to the rise in resistant strains several of these drugs are becoming less and less effective. In bringing a new class of drug into the battle against bacterial with a truly novel mechanism of action we are doing something relatively rare - last seen in 2000.
Our progress has been rapid to date and it is now clear that MGB-BP3 is just the first in our new exciting class of anti-infectives.
Last Updated: June 18th 2013